Influence of spironolactone treatment on endothelial function in non-obese women with polycystic ovary syndrome

The study examined the impact of spironolactone on endothelial function in 30 non-obese women with polycystic ovary syndrome (PCOS), using 20 body mass index-matched control subjects for comparison. Initially, the PCOS patients had significantly lower flow-mediated dilatation (FMD), a measure of endothelial function, than the controls. After receiving 100 mg of spironolactone daily for 6 months, the PCOS patients showed a significant increase in FMD, aligning with the levels of the control group. Although serum androgen levels remained unchanged, there was a significant reduction in total and LDL-cholesterol levels. The study concluded that spironolactone treatment not only normalized endothelial function but also improved cholesterol profiles in non-obese women with PCOS, suggesting potential cardiovascular benefits. However, the small sample size may limit the strength of these findings, and further research is needed to confirm the effects in different PCOS subgroups.